Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    ORIC Pharmaceuticals Inc.

    NASDAQ: ORIC · Real-Time Price · USD
    10.49
    0.26 (2.54%)
    At close: Jun 26, 2025, 3:59 PM
    10.49
    0.00%
    After-hours: Jun 26, 2025, 07:56 PM EDT
    2.54%
    Bid 10.32
    Market Cap 894M
    Revenue (ttm) 533K
    Net Income (ttm) -132.86M
    EPS (ttm) -1.88
    PE Ratio (ttm) -5.58
    Forward PE -6.03
    Analyst Buy
    Ask 10.71
    Volume 797,447
    Avg. Volume (20D) 1,195,535
    Open 10.28
    Previous Close 10.23
    Day's Range 10.13 - 10.65
    52-Week Range 3.90 - 14.67
    Beta 1.48

    About ORIC

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ORIC
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ORIC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    4 weeks ago
    +33.5%
    Oric Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription
    4 weeks ago
    +3.29%
    ORIC Pharmaceuticals shares are trading higher after the company announced preliminary efficacy and safety data from its ongoing Phase 1b trial of ORIC-944. Additionally, the company announced a $125 million private placement, which was priced at an 18% premium to its 10-day trailing volume-weighted average price.
    news image

    1 week ago · zacks.com

    All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

    Oric Pharmaceuticals (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    1 week ago · zacks.com

    Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?

    The consensus price target hints at a 105% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

    news image

    2 weeks ago · zacks.com

    What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?

    Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

    news image

    3 weeks ago · zacks.com

    Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know

    The consensus price target hints at a 131.3% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn...

    news image

    4 weeks ago · zacks.com

    ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

    ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.

    news image

    4 weeks ago · benzinga.com

    ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

    ORIC Pharmaceuticals Inc. ORIC released preliminary efficacy and safety data on Wednesday from its ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors i...

    news image

    2 months ago · seekingalpha.com

    ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech

    ORIC Pharmaceuticals is advancing ORIC-114 for 1st-line EGFR/HER2 exon 20 NSCLC, with comprehensive data expected in the 2nd half of 2025 and a phase 3 trial to start in 2026. ORIC-944 in combination ...

    Add to Watchlist